Eagle Health Investments’s Procept Biorobotics PRCT Stock Holding History

Eagle Health Investments’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-483,815	Closed	-$12.1M	–	31
2026 Q1	$12.1M	Buy	483,815 +175,381	+57%	+$4.94M	2.12%	18
2025 Q4	$9.7M	Hold	308,434	–	–	2.13%	16
2025 Q3	$11M	Buy	308,434 +9,345	+3%	+$427K	2.89%	13
2025 Q2	$17.2M	Hold	299,089	–	–	4.25%	11
2025 Q1	$17.4M	Buy	299,089 +66,000	+28%	+$4.51M	4.52%	11
2024 Q4	$18.8M	Hold	233,089	–	–	4.6%	11
2024 Q3	$18.7M	Sell	233,089 -24,000	-9%	-$1.71M	3.54%	14
2024 Q2	$15.7M	Sell	257,089 -80,129	-24%	-$4.77M	2.75%	17
2024 Q1	$16.7M	Hold	337,218	–	–	3.1%	11
2023 Q4	$14.1M	Hold	337,218	–	–	2.87%	15
2023 Q3	$11.1M	Hold	337,218	–	–	2.44%	16
2023 Q2	$11.9M	Buy	337,218 +53,000	+19%	+$1.75M	2.23%	17
2023 Q1	$8.07M	Buy	+284,218	New	+$10M	1.57%	18

Other funds holding PRCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Eagle Health Investments's PRCT Position: Q2 2026 in Review

Eagle Health Investments sold out of Procept Biorobotics (PRCT) in Q2 2026, closing a stake of 483,815 shares — an estimated $12.1M sold.

Eagle Health Investments first reported a position in PRCT in Q1 2023 and held it in 13 quarters. The position peaked at $18.8M in Q4 2024. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

Eagle Health Investments reported no remaining Procept Biorobotics position as of Q2 2026 after selling out during the quarter.
Eagle Health Investments sold 483,815 Procept Biorobotics shares in Q2 2026, an estimated $12.1M.
Eagle Health Investments first reported a position in Procept Biorobotics in Q1 2023 and held it in 13 quarters.
Eagle Health Investments's Procept Biorobotics position peaked at $18.8M in Q4 2024.
254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Eagle Health Investments's 13F filing for Q2 2026, filed 10 Aug 2026.